Edgewise Therapeutics (EWTX) Accumulated Expenses (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Accumulated Expenses of $8.6 million for Q1 2026, up 8.02% sequentially from $7.9 million in Q4 2025, and up 115.27% YoY from $4.0 million in Q1 2025.
Edgewise Therapeutics (EWTX) Accumulated Expenses (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Accumulated Expenses for 7 years, with the latest figure at $8.6 million in Q1 2026.
- Quarterly Accumulated Expenses rose 115.27% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (up 115.27% YoY) and the FY2025 annual result came in at $7.9 million, up 9.56% from the prior year.
- Accumulated Expenses climbed to $8.6 million in Q1 2026 per EWTX's latest filing, from $7.9 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $8.6 million in Q1 2026 and troughed at $1.3 million in Q1 2022.
- A 5-year average of $5.4 million and a median of $5.8 million in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses jumped 343.46% in 2023, then slumped 51.01% in 2024.
- Over 5 years, Accumulated Expenses stood at $5.8 million in 2022, then increased by 3.96% to $6.1 million in 2023, then gained by 19.07% to $7.2 million in 2024, then gained by 9.56% to $7.9 million in 2025, then climbed by 8.02% to $8.6 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $8.6 million, $7.9 million, and $6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.58 Mn |
| Mar 31, 2026 | 8.56 Mn |
| Dec 31, 2025 | 7.92 Mn |
| Sep 30, 2025 | 6.48 Mn |
| Jun 30, 2025 | 5.64 Mn |
| Mar 31, 2025 | 3.97 Mn |
| Dec 31, 2024 | 7.23 Mn |
| Sep 30, 2024 | 6.13 Mn |
| Jun 30, 2024 | 5.14 Mn |
| Mar 31, 2024 | 2.92 Mn |
| Dec 31, 2023 | 6.07 Mn |
| Sep 30, 2023 | 5.68 Mn |
| Jun 30, 2023 | 6.62 Mn |
| Mar 31, 2023 | 5.97 Mn |
| Dec 31, 2022 | 5.84 Mn |
| Sep 30, 2022 | 2.70 Mn |
| Jun 30, 2022 | 4.26 Mn |
| Mar 31, 2022 | 1.35 Mn |
| Dec 31, 2021 | 3.88 Mn |
| Sep 30, 2021 | 2.03 Mn |